Lenalidomide
Other / unclassified targets CRBN, IKZF1, IRF4, TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | REVLIMID | — | 2006-06-29 – 2019-05-28 | fda.gov ↗ |
| Approved | EU (EMA) | Revlimid | — | 2007-06-14 | europa.eu ↗ |
| Approved | US (FDA) | REVLIMID | — | 2005-12-27 | fda.gov ↗ |
Trials 886 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06209606 | Dec 2022 → May 2026 overdue | plasma cell myeloma | Oncotherapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT03631043 | Dec 2018 → Dec 2025 | smoldering plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02921893 | Oct 2016 → Apr 2022 | POEMS syndrome, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00704691 | Jun 2008 → Jul 2009 | adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified +1 | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 0 | NCT00434239 | Feb 2007 → May 2011 | myelodysplastic syndrome | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 1154 trials | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06015880 | May 2024 → Jun 2027 expected | high grade B-cell lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT06192888 | Jan 2024 → Jan 2028 expected | mantle cell lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06547944 | Jan 2024 → Dec 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05867030 | Jul 2023 → Aug 2029 | follicular lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05641324 | Feb → Jul 2023 | plasma cell myeloma | Anaveon AG | Terminated | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04635683 | Sep 2022 → Dec 2023 | MALT lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, mantle cell lymphoma +2 | Yazeed Sawalha | Withdrawn | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT05211336 | Apr 2022 → Jun 2024 overdue | diffuse large B-cell lymphoma of the central nervous system | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Show all 154 trials opens the full record — a long page | ||||||
| Phase 1/2140 trials | ||||||
| Phase 1/2 | NCT07384624 | Apr 2026 → Jun 2028 expected | HIV infectious disease | Erasmus Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07133763 | Sep 2025 → Sep 2027 expected | Epstein-Barr virus-associated lymphoproliferative disorder | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07133776 | Sep 2025 → Sep 2027 expected | Epstein-Barr virus infection | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06762431 | Nov 2024 → Mar 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Vitebsk Regional Clinical Cancer Centre | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06240520 | Apr 2024 → May 2025 | HIV infectious disease | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT05583617 | Nov 2023 → Jul 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06087653 | Oct 2023 → May 2026 overdue | plasma cell myeloma | Starton Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05861050 | Aug 2023 → Feb 2027 expected | mantle cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05626322 | Aug 2023 → Aug 2024 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded |
| Show all 140 trials opens the full record — a long page | ||||||
| Phase 2462 trials | ||||||
| Phase 2 | NCT07605416 | Jul 2026 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07029776 | Jul 2026 → Apr 2030 expected | plasma cell myeloma | University of Arkansas | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07652905 | Jun 2026 → Jun 2029 expected | plasma cell leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639138 | Jun 2026 → Jun 2028 expected | hepatocellular carcinoma | Shunda Du | Recruiting | No outcome recorded |
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07602322 | May 2026 → May 2028 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07594899 | May 2026 → May 2029 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07485647 | May 2026 → May 2028 expected | plasma cell myeloma | Eden Biltibo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07585747 | Apr 2026 → Dec 2029 expected | follicular lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Show all 462 trials opens the full record — a long page | ||||||
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT07428369 | Jun 2026 → May 2038 | plasma cell myeloma | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT07095452 | Jan 2026 → Jan 2042 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07068165 | Jul 2025 → Jul 2028 expected | immunoglobulin G4-related sclerosing disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03759093 | Sep 2023 → Sep 2025 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2/3 | NCT05665140 | Feb 2023 → Aug 2027 expected | plasma cell myeloma | University Hopsital Schleswig Holstein Campus Lübeck | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02145598 | Aug 2013 → Dec 2017 | plasma cell myeloma | Dr. med. Lars-Olof Muegge | Terminated | No outcome recorded |
| Phase 2/3 | NCT01197560 | Sep 2010 → Jul 2013 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00120120 | Jan 2005 → Oct 2007 | radiculopathy | Celgene Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00055562 | Jan 2003 → Dec 2004 | melanoma, metastatic neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 379 trials | ||||||
| Phase 3 | NCT07649525 | Jul 2026 → Jun 2033 expected | plasma cell leukemia, plasma cell myeloma | University of Leeds | Recruiting | No outcome recorded |
| Phase 3 | NCT06965244 | Oct 2025 → Feb 2029 expected | cutaneous lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06918002 | Jul 2025 → May 2036 expected | plasma cell myeloma | Intergroupe Francophone du Myelome | Recruiting | No outcome recorded |
| Phase 3 | NCT06508658 | Aug 2024 → Mar 2028 expected | diffuse large B-cell lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06284122 | Jun 2024 → Nov 2028 expected | follicular lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 3 | NCT06187441 | May 2024 → Jan 2031 expected | plasma cell myeloma | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06521255 | May 2024 → Sep 2028 expected | diffuse large B-cell lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06191744 | Feb 2024 → Nov 2037 expected | follicular lymphoma | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT06045806 | Oct 2023 → Aug 2025 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05561387 | Oct 2023 → May 2031 expected | plasma cell myeloma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06006117 | Sep 2023 → Sep 2027 expected | marginal zone lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 3 | NCT05429268 | Dec 2022 → Mar 2026 overdue | diffuse large B-cell lymphoma, large B-cell lymphoma | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05558319 | Nov 2022 → Apr 2027 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT05243797 | Sep 2022 → Apr 2028 expected | plasma cell myeloma | European Myeloma Network B.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05351346 | Jun 2022 → Jun 2026 | diffuse large B-cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05179733 | Mar 2022 → Dec 2025 | diffuse large B-cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04824092 | May 2021 → Sep 2026 expected | diffuse large B-cell lymphoma | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04490707 | Sep 2020 → Dec 2022 | acute myeloid leukemia | Ge Zheng | Unknown | No outcome recorded |
| Phase 3 | NCT03993912 | Oct 2019 → Oct 2026 expected | plasma cell myeloma | University Hospital, Lille | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04084626 | Sep 2019 → Jul 2022 | Epstein-Barr virus infection | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04071457 | Aug 2019 → Jul 2029 expected | plasma cell myeloma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03836014 | Jul 2019 → Jul 2026 overdue | plasma cell myeloma | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04298372 | Feb 2019 → Nov 2021 | AL amyloidosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03742297 | Oct 2018 → Jul 2023 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04287660 | Oct 2017 → Jan 2023 | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT02544308 | Mar 2017 → Apr 2026 overdue | primary plasmacytoma of the bone | University College, London | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02516423 | Nov 2016 → Sep 2024 | solitary osseous plasmacytoma | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 3 | NCT02516696 | Feb 2016 → Jun 2022 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 3 | NCT02285062 | Feb 2015 → Mar 2019 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02128061 | Aug 2014 → Nov 2018 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT02215980 | Jul 2014 → Jul 2022 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 3 | NCT02155634 | Jul 2014 → Apr 2017 | monoclonal paraproteinemia disease, plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT02390869 | May 2014 → Jan 2023 overdue | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02112175 | Apr 2014 → Oct 2020 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01996865 | Apr 2014 → May 2024 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01863550 | Dec 2013 → Dec 2026 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01938001 | Nov 2013 → Jun 2018 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01865110 | Nov 2013 → Nov 2020 | mantle cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT01556776 | Jul 2012 → Mar 2016 | B-cell chronic lymphocytic leukemia | German CLL Study Group | Completed | No outcome recorded |
| Phase 3 | NCT01685814 | May 2012 → Sep 2016 | — | Wuerzburg University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01650701 | Feb 2012 → May 2017 | follicular lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT01476787 | Dec 2011 → Apr 2024 | follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01169337 | Jan 2011 → Jan 2019 overdue | light chain deposition disease, smoldering plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01208766 | Jan 2011 → Dec 2020 | plasma cell myeloma | HOVON Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01191060 | Oct 2010 → Nov 2018 | plasma cell myeloma | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 3 | NCT01208662 | Sep 2010 → Feb 2022 overdue | plasma cell myeloma | Paul Richardson, MD | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01098656 | Jul 2010 → Sep 2013 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 3 | NCT02354313 | May 2010 → Dec 2017 | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | No outcome recorded |
| Phase 3 | NCT01021423 | Apr 2010 → Mar 2011 | mantle cell lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01621672 | Apr 2010 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT01029262 | Jan 2010 → Mar 2013 | anemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01243476 | Jan 2010 → Jun 2022 | myelodysplastic syndrome | Fundación General de la Universidad de Salamanca | Completed | No outcome recorded |
| Phase 3 | NCT00988208 | Nov 2009 → Jan 2012 | prostate cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00910910 | Oct 2009 → Mar 2014 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01093196 | Oct 2009 → Nov 2012 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 3 | NCT00928486 | Apr 2009 → Sep 2010 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00891384 | Apr 2009 → Jun 2017 | plasma cell myeloma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Completed | No outcome recorded |
| Phase 3 | NCT01122472 | Apr 2009 → Jun 2016 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT00843882 | Jan 2009 → Jul 2019 overdue | anemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00774345 | Jan 2009 → Oct 2020 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00689936 | Aug 2008 → Jul 2016 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00644228 | Jul 2008 → Nov 2015 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00602641 | Feb 2008 → Jan 2014 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00522392 | Sep 2007 → Aug 2012 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00478777 | Mar → Nov 2007 | refractory plasma cell neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00405756 | Jan 2007 → Nov 2009 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00420849 | Nov 2006 → Oct 2009 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00430365 | Jun 2006 → Sep 2017 | plasma cell myeloma | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 3 | NCT00179647 | Sep 2005 → Dec 2008 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00179621 | Jul 2005 → Jun 2008 | myelodysplastic syndrome | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00114101 | Dec 2004 → Dec 2012 overdue | smoldering plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00098475 | Nov 2004 → Nov 2008 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00064038 | Nov 2004 → Oct 2008 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00093028 | Jan 2004 → Jan 2006 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT00622336 | Apr 2003 → Nov 2013 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00056160 | Jan 2003 → Nov 2005 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00424047 | Jan 2003 → Nov 2005 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00057616 | Oct 2002 → Jul 2005 | melanoma, metastatic malignant neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06409702 | Jun 2024 → Nov 2027 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 4 | NCT06004765 | Aug 2023 → Aug 2024 | myelodysplastic syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05598580 | Nov 2022 → May 2024 | HIV infectious disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05722405 | Jul 2022 → Jun 2026 overdue | plasma cell myeloma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05183139 | Jun 2022 → Dec 2026 | plasma cell myeloma | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT04842318 | Mar 2021 → Mar 2023 | follicular lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04361643 | Oct 2020 → Aug 2021 | COVID-19 | Hospital Universitario Getafe | Unknown | No outcome recorded |
| Phase 4 | NCT04217967 | Sep 2019 → Jun 2024 | plasma cell myeloma | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03934684 | Sep 2019 → Mar 2023 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT04040491 | Sep 2019 → Dec 2020 | peripheral T-cell lymphoma, not otherwise specified | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT04152577 | Jun 2019 → Oct 2021 | B-cell non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04038411 | Apr 2019 → Apr 2021 | mature T-cell and NK-cell non-Hodgkin lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT03908138 | Mar 2019 → Dec 2021 | plasma cell myeloma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03829371 | Jan 2019 → Jan 2027 expected | plasma cell myeloma | University of Turin, Italy | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01198054 | Jan 2011 → Feb 2013 | acute myeloid leukemia | PETHEMA Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT01408199 | Jan → Aug 2010 | cutaneous lupus erythematosus | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07299331 | Jan 2026 → Apr 2031 expected | marginal zone lymphoma | Zhengzhou University | Not yet recruiting | No outcome recorded |
| — | NCT06697483 | Dec 2024 → Dec 2026 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT07072221 | Nov 2024 → Aug 2029 expected | peripheral T-cell lymphoma, not otherwise specified | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT07184424 | May 2023 → Apr 2025 | hepatocellular carcinoma | Beijing Tsinghua Chang Gung Hospital | Completed | No outcome recorded |
| — | NCT05784987 | Apr 2023 → Jan 2024 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05449548 | Apr 2023 → Dec 2026 expected | ulcerative stomatitis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT05477797 | Feb 2023 → Jan 2026 | — | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05488327 | Aug 2022 → Aug 2023 | dermatomyositis | Jiangxi Provincial People's Hopital | Unknown | No outcome recorded |
| — | NCT05797948 | Jul 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT05058755 | Sep 2021 → Dec 2022 | extranodal nasal NK/T cell lymphoma | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT04432402 | Jun 2020 → Dec 2022 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT04319601 | Mar 2020 → Mar 2022 | angioimmunoblastic T-cell lymphoma, chemotherapy-induced toxicity | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04008888 | Jan 2018 → Jan 2020 | chromosome 17p deletion, extramedullary soft tissue plasmacytoma, plasma cell leukemia, plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT01927718 | Jan 2014 → Nov 2016 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT01050790 | Jan 2010 → Aug 2014 | plasma cell myeloma | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01649791 | Jan 2010 → May 2012 | B-cell chronic lymphocytic leukemia | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| — | NCT00890552 | Apr 2009 → Aug 2012 | amyloidosis, leukemia | Stanford University | Completed | No outcome recorded |
| — | NCT00633945 | Nov 2007 → Jul 2009 | cutaneous lupus erythematosus | University of Pennsylvania | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT02856438 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT02368301 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 228 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05846880 Background | Dec 2024 → May 2028 expected | plasma cell myeloma | Amany Keruakous, MD, MS. | Recruiting | No outcome recorded |
| Phase 0 | NCT04049864 Background | Jan 2019 → Dec 2023 | neuroblastoma | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Unknown | No outcome recorded |
| Phase 0 | NCT01861340 Background | May 2014 → Apr 2016 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 140 trials | ||||||
| Phase 1 | NCT07697339 Comparator | Jul 2026 → Aug 2027 expected | mantle cell lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06768489 Background | Dec 2024 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06042725 Background | Mar 2024 → Dec 2028 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05828459 Background | Jul 2023 → Jan 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Onward Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 Background | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05308654 Background | May 2022 → Feb 2024 overdue | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05279300 Background | Mar 2022 → Jun 2027 expected | adult lymphoma | CStone Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04739813 Background | Jul 2021 → May 2026 overdue | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04818372 Background | Apr 2021 → Jan 2023 | plasma cell myeloma | Keymed Biosciences Co.Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04722146 Background | Mar 2021 → Oct 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04519476 Background | Nov 2020 → Dec 2023 | refractory plasma cell neoplasm | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04578600 Background | Oct 2020 → Dec 2023 | MALT lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, hairy cell leukemia +2 | Joseph Tuscano | Completed | No outcome recorded |
| Phase 1 | NCT04405167 Background | Jul 2020 → May 2025 | plasma cell myeloma | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT04326296 Background | May 2020 → Sep 2022 | colorectal cancer | LiNing | Unknown | No outcome recorded |
| Phase 1 | NCT04196491 Background | May 2020 → Jun 2023 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04091126 Background | Dec 2019 → Jun 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03984097 Background | Jul 2019 → Mar 2026 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03591744 Background | Oct 2018 → Oct 2019 | plasma cell leukemia | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03506802 Background | Jul 2018 → Jun 2019 | plasma cell myeloma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03031730 Background | Jun 2018 → Jul 2024 | plasma cell myeloma, plasmacytoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT03150316 Background | May 2017 → Jun 2020 | plasma cell myeloma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03015792 Background | Mar 2017 → Oct 2022 | plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT02918331 Background | Sep 2016 → Oct 2017 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT02697344 Background | Apr 2016 → Oct 2018 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02492750 Background | Apr 2016 → Jun 2019 | indolent plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02721043 Background | Apr 2016 → Nov 2019 | cancer | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1 | NCT02655458 Background | Jan 2016 → Jul 2017 | plasma cell myeloma | Hearn Jay Cho | Completed | No outcome recorded |
| Phase 1 | NCT02426723 Background | Oct 2015 → Oct 2018 | plasma cell myeloma | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02335983 Background | Apr 2015 → Oct 2019 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02280525 Background | Mar 2015 → Jul 2019 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01965353 Background | Oct 2013 → Mar 2019 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01711671 Comparator | May 2013 → Jul 2015 | plasma cell myeloma | Leap Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02481934 Background | Mar 2013 → Jul 2016 | plasma cell myeloma | Joaquín Martínez López, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT01645930 Background | Dec 2012 → Jul 2014 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01583283 Background | Jul 2012 → Mar 2021 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01393964 Background | Jan 2012 → Mar 2014 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01359657 Background | Sep 2011 → Mar 2016 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00884546 Comparator | Jul 2009 → Mar 2012 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00532675 Background | Apr 2008 → Nov 2017 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/239 trials | ||||||
| Phase 1/2 | NCT07600151 Background | Dec 2026 → Sep 2036 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07210047 Comparator | Aug 2025 → Nov 2027 expected | plasma cell myeloma | HuniLife Biotechnology, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07099391 Background | Jul 2025 → Jul 2029 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05573802 Background | Jul 2023 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05771883 Background | May 2023 → May 2025 | B-cell non-Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT07150091 Background | Jul 2022 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05222555 Background | Jul 2022 → Jul 2024 overdue | diffuse large B-cell lymphoma | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05280275 Background | Apr 2022 → Mar 2026 | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 1/2 | NCT05265975 Background | Apr 2022 → Dec 2024 | diffuse large B-cell lymphoma, indolent B-cell non-Hodgkin lymphoma | Antengene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT05201248 Background | Mar 2022 → Apr 2025 overdue | B-cell non-Hodgkin lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04942067 Background | Dec 2021 → Sep 2024 | amyloidosis, plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05205252 Comparator | Dec 2021 → Jul 2023 | refractory hematologic cancer | Epizyme, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05025800 Background | Oct 2021 → Mar 2028 expected | Richter transformation, composite lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +2 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04822337 Background | May 2021 → Apr 2029 expected | plasma cell myeloma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04674514 Background | Apr 2021 → Jan 2024 | plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04663347 Background | Nov 2020 → Sep 2027 expected | diffuse large B-cell lymphoma, follicular lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04446962 Comparator | Oct 2020 → Feb 2035 expected | central nervous system non-hodgkin lymphoma, diffuse large B-cell lymphoma | Institut Curie | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04542824 Background | Aug 2020 → Sep 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma, marginal zone lymphoma +1 | Genmab | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05950165 Background | Jan 2020 → Dec 2026 expected | non-Hodgkin lymphoma | Cho Pharma Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04025450 Background | Jul 2019 → Jul 2029 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03544281 Background | Sep 2018 → Feb 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03505944 Background | Jul 2018 → Dec 2022 | non-Hodgkin lymphoma | Nordic Lymphoma Group | Unknown | No outcome recorded |
| Phase 1/2 | NCT03223610 Background | Feb 2018 → Dec 2026 expected | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03100877 Background | Jan 2018 → May 2020 | plasma cell leukemia, plasma cell myeloma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02206425 Background | Sep 2014 → Jan 2018 | plasma cell myeloma | Oncotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01827137 Background | Apr 2013 → Dec 2016 | plasma cell myeloma | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01668719 Background | Nov 2012 → Feb 2020 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01615029 Background | Jun 2012 → Oct 2015 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01531998 Background | May 2012 → May 2014 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01555281 Background | Feb 2012 → Jun 2022 | plasma cell myeloma | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01502085 Background | Dec 2011 → Dec 2015 | plasma cell myeloma | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 1/2 | NCT01383928 Background | Oct 2011 → Oct 2014 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01348919 Background | Aug 2011 → Mar 2013 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01355705 Background | Aug 2011 → Jul 2016 | plasma cell myeloma | Michaela Liedtke | Completed | No outcome recorded |
| Phase 1/2 | NCT01217957 Background | Nov 2010 → Mar 2013 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00915408 Background | Sep 2006 → Mar 2014 | plasma cell myeloma | King's College Hospital NHS Trust | Completed | No outcome recorded |
| Phase 1/2 | NCT00348595 Comparator | Jul 2006 → Jun 2016 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 259 trials | ||||||
| Phase 2 | NCT07247097 Background | Aug 2026 → Dec 2030 expected | plasma cell myeloma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07505849 Comparator | Mar 2026 → Mar 2030 expected | follicular lymphoma | KeshuZhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06910124 Background | Dec 2025 → Dec 2032 expected | plasma cell myeloma | Dickran Kazandjian, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT07189065 Comparator | Nov 2025 → Dec 2027 expected | diffuse large B-cell lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting | No outcome recorded |
| Phase 2 | NCT07149857 Background | Oct 2025 → Apr 2028 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07081022 Background | Aug 2025 → Apr 2027 expected | B-cell non-Hodgkin lymphoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07045909 Background | Jun 2025 → Mar 2028 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT06931704 Background | May 2025 → Nov 2030 expected | plasma cell myeloma | Nantes University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06758037 Background | Jan 2025 → Dec 2026 expected | diffuse large B-cell lymphoma | First Affiliated Hospital of Ningbo University | Recruiting | No outcome recorded |
| Phase 2 | NCT06594432 Background | Oct 2024 → Dec 2026 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06577025 Background | Aug 2024 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04876248 Background | Aug 2024 → Sep 2026 expected | plasma cell myeloma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06169215 Comparator | Jul 2024 → Sep 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05669989 Background | Apr 2023 → Nov 2026 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05575973 Background | Oct 2022 → Jul 2025 | diffuse large B-cell lymphoma | Jianfeng Zhou | Unknown | No outcome recorded |
| Phase 2 | NCT05469893 Comparator | Aug 2022 → Jul 2030 expected | smoldering plasma cell myeloma | Irene Ghobrial, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05186558 Background | May 2022 → Jan 2024 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05328102 Background | Apr 2022 → Feb 2023 | diffuse large B-cell lymphoma | Xencor, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05032820 Background | Jan 2022 → Aug 2024 | plasma cell myeloma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT04891809 Background | Oct 2021 → Dec 2027 expected | plasma cell myeloma | Study Group of Medical Tumour Therapy (AGMT) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04717700 Background | Aug 2021 → Aug 2025 overdue | plasma cell myeloma | Ida Bruun Kristensen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04653246 Background | Jul 2021 → Dec 2025 overdue | plasma cell myeloma | Jacob Laubach, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04802356 Background | Apr 2021 → Mar 2025 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04277845 Background | Aug 2020 → Mar 2022 | plasma cell myeloma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04133636 Background | Nov 2019 → Feb 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03376477 Background | Sep 2019 → Jan 2024 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT03785184 Background | Apr → Aug 2019 | plasma cell myeloma | AbbVie | Withdrawn | No outcome recorded |
| Phase 2 | NCT03601078 Background | Dec 2018 → Jan 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03673826 Background | Nov 2018 → Aug 2024 overdue | smoldering plasma cell myeloma | HOVON Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03411031 Comparator | Oct 2018 → Feb 2021 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03605056 Background | Jul 2018 → Jul 2020 | plasma cell myeloma | Peng Liu | Unknown | No outcome recorded |
| Phase 2 | NCT03490344 Background | May 2018 → Mar 2023 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03477539 Background | Apr 2018 → May 2022 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03004287 Background | Jul 2017 → Oct 2026 expected | plasma cell myeloma | University of Arkansas | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03000634 Background | Apr 2017 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 2 | NCT02891811 Comparator | Mar 2017 → Mar 2024 | plasma cell myeloma | Study Group of Medical Tumour Therapy (AGMT) | Completed | No outcome recorded |
| Phase 2 | NCT02917941 Background | Nov 2016 → Aug 2019 | refractory plasma cell neoplasm | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT02880228 Background | Sep 2016 → Jul 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02719613 Background | Jul 2016 → Feb 2026 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02728102 Background | Jul 2016 → Jun 2020 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT02720510 Comparator | Jun 2016 → May 2017 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02331368 Background | Jun 2015 → Jun 2017 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02928419 Background | May 2015 → Sep 2018 | myelodysplastic syndrome | Associazione Qol-one | Terminated | No outcome recorded |
| Phase 2 | NCT02272803 Background | Feb 2015 → Feb 2017 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02294357 Background | Dec 2014 → Sep 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02159365 Background | Mar 2014 → Jun 2016 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01729091 Background | Jun 2013 → Jun 2024 | plasma cell leukemia, plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02206503 Background | Mar 2013 → Apr 2015 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 2 | NCT01374217 Background | Apr 2012 → Jan 2014 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT01701076 Background | Mar 2012 → Feb 2016 | plasma cell myeloma | Cantonal Hospital of St. Gallen | Completed | No outcome recorded |
| Phase 2 | NCT01349569 Background | Jan 2012 → Oct 2016 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01501370 Comparator | Jan 2012 | plasma cell myeloma | Tiziana Marangon | Withdrawn | No outcome recorded |
| Phase 2 | NCT01307605 Comparator | Feb 2011 → Jun 2014 | lymphoma | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01242930 Background | Nov 2010 → Nov 2014 | plasma cell myeloma | Geron Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01380106 Comparator | Aug 2010 → Sep 2017 | plasma cell myeloma | Boston VA Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00899431 Comparator | May 2009 → Oct 2018 | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00742560 Background | Aug 2008 → Oct 2016 | hematopoietic and lymphoid cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00957385 Comparator | Jun 2008 → Apr 2015 | acute myeloid leukemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00628238 Comparator | Feb 2008 → Feb 2011 | B-cell chronic lymphocytic leukemia | Chronic Lymphocytic Leukemia Research Consortium | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06324266 Comparator | Apr 2023 → Dec 2025 | plasma cell myeloma | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2/3 | NCT02419118 Background | Jan → Oct 2015 | plasma cell myeloma | Vejle Hospital | Completed | No outcome recorded |
| Phase 376 trials | ||||||
| Phase 3 | NCT07665450 Comparator | Sep 2026 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07285239 Background | Jul 2026 → Nov 2031 expected | plasma cell myeloma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07671287 Background | Jun 2026 → Feb 2031 expected | plasma cell myeloma | University of Heidelberg Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07562022 Background | May 2026 → May 2028 expected | follicular lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07355283 Background | Feb 2026 → Jul 2028 expected | B-cell neoplasm | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07297329 Background | Dec 2025 → Dec 2027 expected | plasma cell myeloma | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06932562 Background | Dec 2025 → Dec 2036 expected | plasma cell myeloma | European Myeloma Network B.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06911502 Comparator | Jul 2025 → Apr 2028 expected | follicular lymphoma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06679101 Background | Dec 2024 → Apr 2031 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06220032 Background | Aug 2024 → Dec 2028 expected | diffuse large B-cell lymphoma | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06522555 Background | Jul 2024 → Aug 2028 expected | diffuse large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06182774 Background | Apr 2024 → Jan 2032 expected | plasma cell myeloma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06313996 Comparator | Mar 2024 → Oct 2031 | B-cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT06149286 Background | Dec 2023 → Jan 2029 expected | marginal zone lymphoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06082102 Comparator | Dec 2023 → Aug 2028 expected | marginal zone lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06084936 Comparator | Oct 2023 → Aug 2027 expected | lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05257083 Background | Oct 2023 → Jun 2033 expected | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05888493 Comparator | Oct 2023 → Jul 2028 expected | follicular lymphoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05827016 Comparator | Jun 2023 → Mar 2029 expected | plasma cell myeloma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05804032 Background | Apr 2023 → Jan 2026 | plasma cell myeloma | University of Heidelberg Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT05438043 Background | Dec 2022 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05623020 Background | Nov 2022 → Oct 2030 expected | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05552222 Background | Oct 2022 → Apr 2031 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05371093 Comparator | Sep 2022 → Oct 2030 expected | lymphoma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05409066 Background | Sep 2022 → Dec 2029 expected | follicular lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05802992 Background | Mar 2022 → Dec 2024 | plasma cell myeloma | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 3 | NCT05317416 Comparator | Mar 2022 → Aug 2027 expected | plasma cell myeloma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05100862 Comparator | Mar 2022 → Jul 2028 expected | marginal zone lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03941860 Background | Feb 2022 → Aug 2023 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT04712097 Background | Oct 2021 → Jun 2026 overdue | B-cell neoplasm | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04923893 Background | Aug 2021 → Feb 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04751877 Background | Jul 2021 → Jun 2024 overdue | plasma cell myeloma | Poitiers University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04834024 Comparator | Jun 2021 → Mar 2025 overdue | indolent B-cell non-Hodgkin lymphoma | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04680052 Background | Apr 2021 → Feb 2024 overdue | follicular lymphoma, marginal zone lymphoma | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04566328 Background | Feb 2021 → Dec 2027 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04483739 Background | Sep 2020 → Jul 2025 overdue | plasma cell myeloma | European Myeloma Network B.V. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04404283 Background | Aug 2020 → Jan 2026 overdue | diffuse large B-cell lymphoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03720041 Comparator | Aug 2020 → Dec 2024 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 3 | NCT04270409 Background | Jun 2020 → Oct 2030 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04224493 Background | Jun 2020 → Feb 2027 expected | follicular lymphoma | Epizyme, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04288765 Background | Mar 2020 → Dec 2024 | plasma cell myeloma | Grupo Cooperativo de Hemopatías Malignas | Withdrawn | No outcome recorded |
| Phase 3 | NCT03937635 Background | Sep 2019 → Dec 2029 expected | smoldering plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04096066 Background | Jul 2019 → Jan 2026 overdue | plasma cell myeloma | Fondazione EMN Italy Onlus | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03570892 Comparator | May 2019 → May 2021 | non-Hodgkin lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03859427 Comparator | May 2019 → Mar 2023 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT03729804 Background | May 2019 → Dec 2026 expected | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03901963 Background | Apr 2019 → Apr 2024 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03952091 Comparator | Mar 2019 → Jun 2024 | plasma cell myeloma | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03710603 Background | Dec 2018 → Aug 2023 overdue | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03652064 Background | Nov 2018 → May 2024 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03617731 Background | Oct 2018 → Jun 2028 expected | plasma cell myeloma | University of Heidelberg Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03948035 Background | Aug 2018 → Aug 2029 expected | plasma cell myeloma | Wuerzburg University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03319667 Background | Dec 2017 → Apr 2027 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02659293 Comparator | Apr 2016 → Nov 2027 expected | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02579863 Background | Oct 2015 → Jul 2018 | plasma cell myeloma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02575144 Background | Sep 2015 → Oct 2024 | plasma cell myeloma | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT02495922 Background | Jun 2015 → Jun 2021 | plasma cell myeloma | University of Heidelberg Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02322320 Comparator | Mar 2015 → Jun 2019 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT02252172 Comparator | Feb 2015 → Sep 2018 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02406144 Background | Nov 2014 → Sep 2017 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT02076009 Background | Jul 2014 → Mar 2016 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01891643 Background | Sep 2013 → Jun 2020 | indolent plasma cell myeloma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT01916252 Comparator | Sep 2013 → Nov 2016 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01850524 Comparator | Apr 2013 → Dec 2019 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01659658 Comparator | Dec 2012 → Jul 2022 | AL amyloidosis | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01564537 Background | Aug 2012 → Oct 2014 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01335399 Background | Aug 2011 → Oct 2019 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01239797 Background | Jun 2011 → Sep 2014 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01080391 Background | Jul 2010 → Jun 2014 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01554852 Comparator | May 2010 → Dec 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 3 | NCT01109004 Comparator | May 2010 → Jan 2017 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT01090089 Comparator | Mar 2010 → Jan 2020 | plasma cell myeloma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Completed | No outcome recorded |
| Phase 3 | NCT01091831 Comparator | Jul 2009 → Sep 2021 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 3 | NCT01530594 Comparator | Jan 2009 → Jan 2013 | plasma cell myeloma | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 3 | NCT00551928 Comparator | Jun 2007 → Jun 2022 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07334535 Comparator | Jan 2026 → Jul 2028 expected | plasma cell myeloma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07025005 Comparator | Aug 2025 → Jun 2026 overdue | peripheral neuropathy, plasma cell myeloma | Tanta University | Recruiting | No outcome recorded |
| Phase 4 | NCT04348006 Background | Mar 2020 → Jul 2021 | plasma cell myeloma | Al-Rasheed University College | Withdrawn | No outcome recorded |
| Phase 4 | NCT03416374 Background | Feb 2018 → May 2021 | refractory plasma cell neoplasm | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT03173092 Background | Nov 2017 → Mar 2026 | plasma cell myeloma | Takeda | Terminated | No outcome recorded |
| Phase 4 | NCT01731886 Comparator | Sep 2012 → Apr 2017 | plasma cell myeloma | Columbia University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00907452 Comparator | Jul 2009 → Dec 2010 | plasma cell myeloma | Intergroupe Francophone du Myelome | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02666209 Background | — | plasma cell myeloma | Dana-Farber Cancer Institute | No longer available | No outcome recorded |
Press releases naming this drug 16 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-06 | AbbVie | AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma abbvie.com ↗ |
| 2026-06-29 | AbbVie | AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma abbvie.com ↗ |
| 2026-06-19 | Incyte Corporation | Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) incyte.com ↗ |
| 2025-12-22 | Incyte Corporation | Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma incyte.com ↗ |
| 2025-11-18 | AbbVie | AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma abbvie.com ↗ |
| 2025-06-18 | Incyte Corporation | Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma incyte.com ↗ |
| 2023-03-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S. tevapharm.com ↗ |
| 2022-03-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S. tevapharm.com ↗ |
| 2022-02-18 | Novartis Pharmaceuticals | Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine novartis.com ↗ |
| 2021-12-11 | Incyte Corporation | MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma incyte.com ↗ |
| 2021-08-26 | Incyte Corporation | Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma incyte.com ↗ |
| 2021-06-25 | Incyte Corporation | Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma incyte.com ↗ |
| 2021-06-04 | Incyte Corporation | Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL incyte.com ↗ |
| 2021-04-19 | Incyte Corporation | Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma incyte.com ↗ |
| 2020-12-07 | Incyte Corporation | Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020 incyte.com ↗ |
| 2020-07-31 | Incyte Corporation | FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) incyte.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 1,128 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lenalidomide | “APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg...” NCT04942067 ↗1086“The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed...” NCT04842318 ↗ “The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large...” NCT06764017 ↗ “Eligible patients with transplant-eligible relapsed/refractory DLBCL will receive 2-4 cycles (21 days per cycle) of tafasitamab combined with lenalidomide and standard...” NCT07621406 ↗ “Targeting Bruton's tyrosine kinase (BTK), the novel BTK inhibitor zanubrutinib (highly selective, low toxicity) combined with obinutuzumab (enhanced antibody-dependent...” NCT07165769 ↗ “Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects...” NCT00179712 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed...” NCT03224507 ↗ “Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally on Days 1-21), and chidamide (30 mg orally twice weekly) in 28-day cycles for up to 6 cycles.” PMID 42124356 ↗ May 2026 “A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer” NCT00179686 ↗ “Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.” NCT05050630 ↗ “Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma” NCT06158269 ↗ “ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗ “the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.” NCT06594432 ↗ “The primary objective is to assess the efficacy and safety of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (Dara-VRD) followed by cilta-cel in high-risk SMM.” NCT06574126 ↗ “Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle” NCT05828459 ↗ “we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL” PMID 38113470 ↗ Jan 2024 “This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex)” PMID 20724537 ↗ Aug 2010 “Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth.” NCT01440582 ↗ “Lenalidomide is designed to change the body's immune system and may also interfere with the development of tiny blood vessels that help support tumor growth.” NCT00759603 ↗ “After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.” NCT00925821 ↗ “Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth.” NCT01502085 ↗ “Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).” NCT02302469 ↗ “Patients enrolled in the study receive a combination therapy of NB02, Rituximab and lenalidomide according to the criteria specified in the protocol.” NCT06737250 ↗ “A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas” NCT00179751 ↗ “Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients” NCT04025450 ↗ “In a phase I study heavily pretreated patients with relapsed or refractory myeloma were treated with CC-5013 (RevlimidTM, lenalidomide).” NCT00306813 ↗ “Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy” NCT03570892 ↗ “Participants were to receive 15 mg oral lenalidomide on days 1-14 of six 21-day cycles, and standard doses of R-CHOP21 chemotherapy” PMID 24831981 ↗ May 2014 “A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles” NCT02390869 ↗ “Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months.” NCT00166413 ↗ “Lenalidomide (Revlimid® CC-5013) with Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma” NCT00179725 ↗ “Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM).” PMID 29673108 ↗ Apr 2018 “VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21” NCT05870917 ↗ “Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.” PMID 24668858 ↗ Apr 2014 “Induction regimen:Patients will start induction treatment with association of Lenalidomide and Prednisone (RP).” NCT01160107 ↗ “Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone” NCT05231629 ↗ “Lenalidomide is an immunomodulatory agent with antiangiogenic, immunoregulatory, and antitumor properties.” NCT07639138 ↗ “The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma” NCT00622336 ↗ “treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.” NCT06748521 ↗ “Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle.” NCT01547260 ↗ “Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days.” NCT04008888 ↗ “Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle.” NCT04674514 ↗ “Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer” NCT00179738 ↗ “A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent” NCT01111903 ↗ “Acalabrutinib, lenalidomide, rituximab will be given as described in the "Arms" decriptions.” NCT04094142 ↗ “including Revlimid (lenalidomide), once daily on days 1-21 followed by a 7 day rest period” NCT01237249 ↗ “All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy.” NCT06758037 ↗ “Lenalidomide, which will be taken by mouth during the first 2 weeks of each 21-day cycle” NCT00942578 ↗ “Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21” NCT04288765 ↗ “patients received 20 mg of Lenalidomide once daily by mouth from day 1 to day 21” NCT07505849 ↗ “Lenalidomide, will be added after two cycles of therapy have been completed.” NCT06517017 ↗ “Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide” NCT01160484 ↗ “azacitidine subcutaneously on days 1-5 and oral lenalidomide on days 6-21.” NCT01050790 ↗ “Revlimid (lenalidomide) (ViPOR-P) in relapsed/refractory B-cell lymphomas” NCT04739813 ↗ “IN Type: Glofitamab + PD-1 inhibitor (e.g., Tislelizumab) + Lenalidomide” NCT07602322 ↗ “Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:” NCT06674096 ↗ “PR/SD: Switch to orelabrutinib + rituximab + lenalidomide for 6 cycles.” NCT07448324 ↗ “In every cycle, lenalidomide was administered at 10-25 mg (days 1-21).” NCT05802992 ↗ “Lenalidomide as outlined in Phase I and Phase II Treatment Arms.” NCT00831766 ↗ “IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone” NCT04405167 ↗ “Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.” NCT07072221 ↗ “Lenalidomide 25mg/day po D1-10 if without gene mutation above.” NCT04480099 ↗ “Lenalidomide: on days 1\~21 of repeated 28 day cycles” NCT03150316 ↗ “Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o.” NCT02983097 ↗ “oral lenalidomide (25 mg daily on days 1-21)” NCT04991103 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05850286 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05979363 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05860036 ↗ “Lenalidomide (Revlimid)/Dexamethasone” NCT01711671 ↗ “* Drug: lenalidomide Oral Capsule” NCT06033820 ↗ “Lenalidomide (Revlimid®, CC-5013)” NCT00179699 ↗ “Lenalidomide 25 mg p.o. day 1-21” NCT01701076 ↗ “combined with oral lenalidomide” PMID 39007066 ↗ Jun 2024 “Lenalidomide PO daily Day 1-21.” NCT01241786 ↗ “fixed dose of oral lenalidomide” NCT00179608 ↗ “Lenalidomide: 25mg, po, d1-21” NCT03908138 ↗ “lenalidomide 25mg/d po D1-10” NCT04152577 ↗ “Lenalidomide oral 20 mg/day” NCT03054532 ↗ “Lenalidomide(REVLIMID®)” NCT00538733 ↗ “Lenalidomide: Oral use.” NCT01185262 ↗ “Lenalidomide 25mg” NCT03208218 ↗ “lenalidomide” NCT04348006 ↗ “Lenalidomide” NCT01133743 ↗ “Lenalidomide” NCT03837873 ↗ “lenalidomide” NCT04348006 ↗ |
| Known as | CC-5013 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗38“A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously...” NCT01476787 ↗ “A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer” NCT00179686 ↗ “A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)” NCT00525447 ↗ “In a phase I study heavily pretreated patients with relapsed or refractory myeloma were treated with CC-5013 (RevlimidTM, lenalidomide).” NCT00306813 ↗ “Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors” NCT00253344 ↗ “Lenalidomide (Revlimid® CC-5013) with Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma” NCT00179725 ↗ “single-agent lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma” NCT00413036 ↗ “Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects.” PMID 18161005 ↗ Dec 2007 “Lenalidomide (CC-5013, Revlimid; Celgene Corporation) is an oral thalidomide analogue with anti-cancer activity.” NCT00322985 ↗ “Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)” NCT00352794 ↗ “Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer” NCT00179738 ↗ “Lenalidomide, initially known as CC-5013, is an analogue of the immunomodulator Drug Thalidomide” NCT01243476 ↗ “Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma” NCT00466921 ↗ “Lenalidomide (CC-5013) is a substance in the class of immunomodulatory agents.” NCT01704781 ↗ “Patients receive oral lenalidomide (CC-5013) once daily on days 1-21.” NCT00096044 ↗ “Single-Agent Lenalidomide (Revlimid®, CC-5013)” NCT00179673 ↗ “Lenalidomide (Revlimid®, CC-5013)” NCT00179699 ↗ “Revlimid (CC-5013, Lenalidomide)” NCT00348595 ↗ “Lenalidomide (CC-5013)” NCT01155505 ↗ “Lenalidomide (CC-5013)” NCT00120120 ↗ “Revlimid (CC-5013)” NCT00396045 ↗ “CC5013” NCT01076543 ↗ |
| Known as | CC-5103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00142168 ↗ |
| Known as | CDC-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00044018 ↗ |
| Known as | Leavdo | “Lenalidomide [Leavdo®]” NCT04604028 ↗ |
| Known as | LEN | “This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 202311“PURPOSE: Single-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free...” PMID 30653422 ↗ Jan 2019 “We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids...” PMID 38643346 ↗ Apr 2024 “The CD30-targeted, antibody-drug conjugate brentuximab vedotin (BV) and the immunomodulator lenalidomide (Len) have demonstrated promising activity as single agents in this population.” PMID 34780623 ↗ Mar 2022 “The Southwest Oncology Group conducted a randomized trial comparing lenalidomide (LEN) plus dexamethasone (DEX; n = 97) to placebo (PLC) plus DEX (n = 95) in newly diagnosed myeloma.” PMID 20876454 ↗ Sep 2010 “we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL.” PMID 27354719 ↗ Jun 2016 “the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential.” PMID 34320785 ↗ Jul 2022 “Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)” NCT03413800 ↗ “Lenalidomide (LEN) and rituximab (RTX) have independently improved progression-free survival (PFS) in CLL” PMID 38856101 ↗ Jun 2024 “Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd)” NCT03651128 ↗ “lenalidomide (LEN) and eltrombopag olamine (ELT)” NCT01772420 ↗ “Lenalidomide (Len)” NCT00786851 ↗ |
| Known as | Lenalidomide (REVLIMID) | “Lenalidomide (REVLIMID®)” NCT01206205 ↗4“Lenalidomide (REVLIMID®)” NCT01191060 ↗ “Lenalidomide (Revlimid)” NCT01297764 ↗ “Lenalidomide (Revlimid)” NCT01307605 ↗ “Lenalidomide: REVLIMID” NCT01185262 ↗ |
| Known as | lenalidomide capsules | “lenalidomide capsules” NCT07184424 ↗ |
| Known as | Lenalomide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03601078 ↗ |
| Known as | NSC #703813 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗1“A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)” NCT01145495 ↗ |
| Known as | Rev | “lenalidomide (Rev) in patients with MM.” PMID 22816680 ↗ Jul 2012 |
| Known as | Revlamid | “Revlamid® (Lenalidomide)” NCT01245673 ↗ |
| Known as | Revlimid | “A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell...” NCT01556035 ↗80“The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗ “Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in...” NCT01029054 ↗ “This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa...” NCT01611259 ↗ “Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug...” NCT00633945 ↗ “Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects...” NCT00179712 ↗ “Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic...” NCT01754870 ↗ “A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With...” NCT00963105 ↗ “The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide,...” NCT00901615 ↗ “The purpose of the first part is to find the highest dose of a drug called lenalidomide (Revlimid®) that can be given in combination with high dose melphalan without causing...” NCT01142232 ↗ “Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly...” NCT02112175 ↗ “The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured...” NCT01348503 ↗ “A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer” NCT00179686 ↗ “Lenalidomide (Revlimid) in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (CLL)” NCT01133743 ↗ “Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles.” NCT00151203 ↗ “A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma” NCT00538824 ↗ “After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.” NCT00925821 ↗ “Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)” NCT00968331 ↗ “A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas” NCT00179751 ↗ “Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors” NCT00253344 ↗ “Quadruplet therapy with Isa-VRd (isatuximab, Velcade [bortezomib], Revlimid [lenalidomide], and dexamethasone) followed by Isa-Rd” PMID 41758929 ↗ Jun 2026 “Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months.” NCT00166413 ↗ “Lenalidomide (Revlimid®) is a thalidomide derivative and belongs to the so-called ImiDs, a class of immunostimulatory molecules.” NCT01166035 ↗ “A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis” NCT00564889 ↗ “Lenalidomide (Revlimid® CC-5013) with Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma” NCT00179725 ↗ “Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.” NCT01342692 ↗ “Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL” NCT01241786 ↗ “Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles.” NCT02575144 ↗ “Lenalidomide (CC-5013, Revlimid; Celgene Corporation) is an oral thalidomide analogue with anti-cancer activity.” NCT00322985 ↗ “Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma” NCT01132989 ↗ “Lenalidomide (Revlimid®) belongs to a proprietary class of compounds called immunomodulatory drugs (IMiDs).” NCT01547260 ↗ “Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma” NCT01939327 ↗ “Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects” NCT02538965 ↗ “Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer” NCT00179738 ↗ “Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).” NCT01243476 ↗ “A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent” NCT01111903 ↗ “Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma” NCT00466921 ↗ “KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab)” NCT03224507 ↗ “Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP)” NCT01352338 ↗ “bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen” NCT07025005 ↗ “Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.” NCT06177028 ↗ “Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg;” NCT03031483 ↗ “Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone” NCT00807599 ↗ “the drug, lenalidomide (Revlimid®), on neuropathy” NCT00665652 ↗ “lenalidomide (Revlimid) and romidepsin (Istodax)” NCT01742793 ↗ “Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14” NCT01206205 ↗ “Single-Agent Lenalidomide (Revlimid®, CC-5013)” NCT00179673 ↗ “lenalidomide (Revlimid) administered orally” NCT01582776 ↗ “Lenalidomide (Revlimid)/Dexamethasone” NCT01711671 ↗ “Lenalidomide (Revlimid®, CC-5013)” NCT00179699 ↗ “AVD Plus Lenalidomide (Revlimid)” NCT01056679 ↗ “Drug: lenalidomide (Revlimid®)” NCT01916252 ↗ “Drug: Revlimid (Lenalidomide)” NCT00778752 ↗ “Lenalidomide (Revlimid®)” NCT05583071 ↗ “Lenalidomide (Revlimid®)” NCT01062152 ↗ “Lenalidomide (Revlimid®)” NCT06918002 ↗ “Revlimid® (lenalidomide)” NCT01379274 ↗ “Lenalidomide (Revlimid)” NCT06863584 ↗ “Lenalidomide(REVLIMID®)” NCT00538733 ↗ “Revlimid (lenalidomide)” NCT00507442 ↗ “Revlimid (lenalidomide)” NCT03223610 ↗ “CC-5013 (Revlimid™)” NCT00093028 ↗ |
| Known as | Revlimid (lenalidomide) | “Revlimid (lenalidomide)” NCT01554852 ↗1“Revlimid (lenalidomide)” NCT00783367 ↗ |
| Known as | Revlimid for Lenalidomide | “Revlimid for Lenalidomide” NCT01270932 ↗ |
| Known as | RevlimidTM | “Lenalidomide (RevlimidTM ) and GM-CSF” NCT00939510 ↗ |
| Action | Inhibit | “inhibiting TNF-alfa secretion” NCT00396045 ↗ |
| Modality | Other / unclassified | “Lenalidomide is an immunomodulatory agent” PMID 28771673 ↗ Aug 2017 |
| Route | Oral | “Patients were treated on a modified Fibronacci dose escalation scheme with an oral daily dose of lenalidomide.” PMID 19451403 ↗ Jun 2009 |
| Target | TNF | “inhibiting TNF-alfa secretion” NCT00396045 ↗ |